EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Development of HPLC-MS/MS Method for Simultaneous Detection of Esketamine and Norketamine: Application to Pharmacokinetics Drug Interactions Affected by Dexmedetomidine

Wei Zhou, Zhe Guo, Xianghan Zhang, Wenjiong Wang, Zhongfeng Zheng, Xaingjun Qiu iD

Drug Design, Development and Therapy · 2025-09 · Volume 19 · 8589-8600

DOI: 10.2147/dddt.s553389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-09. Verfasst von Wei Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Nanyang City Central Hospital, Nanyang, Henan, 473009, People's Republic of China. Hauptthemen laut MEDLINE: Dexmedetomidine, Tandem Mass Spectrometry, Ketamine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Dexmedetomidine (DEX) and esketamine (ESK) are often used together during anesthesia. This study aimed to establish a sensitive and reliable HPLC-MS/MS method for simultaneous quantification of ESK and its active metabolite norketamine (NORK) in beagle dog plasma and to investigate the pharmacokinetic drug-drug interactions (DDIs) between DEX and ESK/NORK.

Methods

A simple protein precipitation method using acetonitrile was applied for plasma sample preparation. After chromatographic separation, analytes were detected by HPLC-MS/MS in positive ion mode using multiple reaction monitoring (MRM). The mass transitions were m/z 238.10→ 125.10 for ESK, m/z 224.10→ 125.10 for NORK, and m/z 354.20→ 209.00 for the internal standard (proadifen). Six beagle dogs were intramuscularly administered 1 mg/kg ESK alone in the first period (ESK group). After a washout, the same dogs received intravenous DEX (2 μg/kg) for 7 consecutive days, followed by co-administration of ESK (DEX+ESK group). The pharmacokinetic parameters of ESK and NORK were calculated using DAS software. Independent-sample t test was used to compare the differences of pharmacokinetic parameters between ESK group and DEX+ESK group, and P < 0.05 indicated a statistically significant difference.

Results

Both ESK and NORK exhibited good linearity within the concentration range of 1– 400 ng/mL, and the methodological validation met the requirements. When ESK was used in combination with DEX, the main pharmacokinetic parameters of ESK and NORK changed, the C max , AUC (0– 24) and AUC (0-∞) of ESK increased, the C max , of NORK decreased, and the AUC (0– 12) and AUC (0-∞) of NORK increased too.

Conclusion

A novel HPLC-MS/MS method was developed and validated and successfully applied to simultaneously quantify ESK and NORK in beagle dog plasma. The pharmacokinetic DDI results indicate that DEX could inhibit the metabolism of ESK, alter pharmacokinetic characteristics of ESK and its metabolite NORK, and significantly increase the systemic exposure of both ESK and NORK. Keywords: dexmedetomidine, esketamine, norketamine, pharmacokinetics, drug-drug interactions, beagle dog

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineTandem Mass SpectrometryKetamineAnimalsDogsChromatography, High Pressure LiquidDrug InteractionsMaleLiquid Chromatography-Mass Spectrometry

Stichwörter der Autor:innen

beagle dogdexmedetomidinedrug-drug interactionsesketaminenorketaminepharmacokinetics

Substanzen

DexmedetomidineKetaminenorketamineEsketamine

Autor:innen und Institutionen

  • Department of Anesthesiology, Nanyang City Central Hospital, Nanyang, Henan, 473009, People's Republic of China.
  • College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, 471023, People's Republic of China.
  • Department of Forensic Toxicology, Henan Yicheng Judicial Appraisal Center, Zhengzhou, Henan, 450052, People's Republic of China.

ORCID-Profile: Xaingjun Qiu

Zitieren

APA

Zhou, W., Guo, Z., Zhang, X., Wang, W., Zheng, Z., & Qiu, X. (2025). Development of HPLC-MS/MS Method for Simultaneous Detection of Esketamine and Norketamine: Application to Pharmacokinetics Drug Interactions Affected by Dexmedetomidine. Drug Design, Development and Therapy, Volume 19, 8589-8600. https://doi.org/10.2147/dddt.s553389

Vancouver

Zhou W, Guo Z, Zhang X, Wang W, Zheng Z, Qiu X. Development of HPLC-MS/MS Method for Simultaneous Detection of Esketamine and Norketamine: Application to Pharmacokinetics Drug Interactions Affected by Dexmedetomidine. Drug Design, Development and Therapy. 2025;Volume 19:8589-8600. doi:10.2147/dddt.s553389

BibTeX
@article{Zhou2025,
  author = {Zhou, Wei and Guo, Zhe and Zhang, Xianghan and Wang, Wenjiong and Zheng, Zhongfeng and Qiu, Xaingjun},
  title = {Development of HPLC-MS/MS Method for Simultaneous Detection of Esketamine and Norketamine: Application to Pharmacokinetics Drug Interactions Affected by Dexmedetomidine},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {8589--8600},
  doi = {10.2147/dddt.s553389}
}
Kostenlos starten →